A comprehensive review on the role of human epidermal growth factor receptor 2 (HER2) as a biomarker in extra-mammary and extra-gastric cancers

F Amisha, P Malik, P Saluja, N Gautam, TH Patel… - Onco, 2023 - mdpi.com
Simple Summary Human epidermal growth factor receptors (HERs) are present in our body
and are responsible for regulating cell growth. When there is an overexpression of …

Antibody-dependent cell-mediated cytotoxicity through Natural Killer (NK) cells: Unlocking NK cells for future immunotherapy

DS Chin, CSY Lim, F Nordin, N Arifin… - Current Pharmaceutical …, 2022 - ingentaconnect.com
Background: Natural killer (NK) cells have potent effector functions that can be further
improved for therapeutic purposes through antibody-dependent cell-mediated cytotoxicity …

Clinically-driven design of synthetic gene regulatory programs in human cells

DV Israni, HS Li, KA Gagnon, JD Sander, KT Roybal… - bioRxiv, 2021 - biorxiv.org
Synthetic biology seeks to enable the rational design of regulatory molecules and circuits to
reprogram cellular behavior. The application of this approach to human cells could lead to …

Ratiometric fluorescence monitoring of antibody-guided drug delivery to cancer cells

D Poplinger, M Bokan, A Hesin… - Bioconjugate …, 2021 - ACS Publications
Ratiometric measurements utilizing two independent fluorescence signals from a dual-dye
molecular system help to improve the detection sensitivity and quantification of many …

Determination of optimum vitamin D3 levels for NK cell-mediated rituximab-and obinutuzumab-dependent cellular cytotoxicity

F Neumann, F Acker, C Schormann… - Cancer Immunology …, 2018 - Springer
Abstract Vitamin D3 (25-OH-D3) deficiency impairs rituximab-dependent cellular cytotoxicity
and the outcome of patients with diffuse large B-cell and follicular lymphomas (DLBCL) …

Transcriptome Analysis in Mexican Adults with Acute Lymphoblastic Leukemia

GM Cruz-Miranda, I Olarte-Carrillo… - International Journal of …, 2024 - mdpi.com
Acute lymphoblastic leukemia (ALL) represents around 25% of adult acute leukemias.
Despite the increasing improvement in the survival rate of ALL patients during the last …

Treating adults with acute lymphocytic leukemia: new pharmacotherapy options

X Thomas, C Le Jeune - Expert Opinion on Pharmacotherapy, 2016 - Taylor & Francis
Introduction: Advances in acute lymphocytic leukemia (ALL) therapy has led to long-term
survival rates in children. However, only 30%-40% of adults achieve long-term disease-free …

Modification of NK cell subset repartition and functions in granulocyte colony-stimulating factor-mobilized leukapheresis after expansion with IL-15

Y Xiong, M Mouginot, L Reppel, C Qian, J Stoltz… - Immunologic …, 2017 - Springer
The ability of natural killer (NK) cells to kill tumor cells without antigen recognition makes
them appealing as an adoptive immunotherapy. However, NK cells are not routinely used in …

Příprava a charakterizace chimerických antigenních receptorů

P Ptáčková - 2021 - dspace.cuni.cz
Pozadí problematiky: Adoptivní terapie pomocí T-buněk s chimerickými antigenními
receptory (CAR) specifickými na CD19 představuje slibnou léčbu relabujících nebo …

Expression of HER2/Neu in B-Cell Acute Lymphoblastic Leukemia

S Rodriguez-Rodriguez, A Pomerantz… - Revista de …, 2017 - medigraphic.com
Background: The expression of HER2/neu in B-cell acute lymphoblastic leukemia has been
reported in previous studies. Objective: The objective of this research was to study the …